Mizuho analyst Joseph Catanzaro initiated coverage of Upstream Bio (UPB) with an Outperform rating and $51 price target The company’s lead program verekitug is well positioned for a positive Phase II readout in asthma in Q1, the analyst tells investors in a research note. The firm projects $2.7B in risk-adjusted 2035 worldwide sales for verekitug and expects the positive Phase II data to drive share outperformance.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UPB:
- Upstream Bio initiated with an Outperform at LifeSci Capital
- 3 Best Stocks to Buy Now, 11/26/2025, According to Top Analysts
- Promising Outlook for Upstream Bio, Inc. Driven by Verekitug’s Clinical Advancements
- Upstream Bio initiated with an Outperform at Evercore ISI
- Upstream Bio, Inc.’s Verekitug: A Promising Buy with Blockbuster Potential in Asthma and COPD Markets